Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Louisville, KY
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Louisville, KY
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Great Falls, MT
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Great Falls, MT
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Bismarck, ND
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bismarck, ND
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Morgantown, WV
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Morgantown, WV
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Aliskiren in Patients With Idiopathic Membranous Nephropathy
A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy
Status: Archived
Mayo Clinic College of Medicine
mi
from
Rochester, MN
Aliskiren in Patients With Idiopathic Membranous Nephropathy
A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy
Status: Archived
Updated: 1/1/1970
Mayo Clinic College of Medicine
mi
from
Rochester, MN
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Chicago, IL
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Chicago, IL
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Kalamazoo, MI
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Kalamazoo, MI
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Brookhaven, MS
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Brookhaven, MS
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
St. Ann, MO
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
St. Ann, MO
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Las Vegas, NV
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Las Vegas, NV
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Columbia, TN
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Columbia, TN
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Fresenius Medical Care North America
mi
from
Irving, TX
A Safety Study of Pentoxifylline for the Treatment of Anemia
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis
Status: Archived
Updated: 1/1/1970
Fresenius Medical Care North America
mi
from
Irving, TX
Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study
Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study: An Investigator Initiated Study
Status: Archived
Harbor-UCLA/MFI Dialysis
mi
from
Long Beach, CA
Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study
Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study: An Investigator Initiated Study
Status: Archived
Updated: 1/1/1970
Harbor-UCLA/MFI Dialysis
mi
from
Long Beach, CA
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Clinical Research Facility
mi
from
Duluth, MN
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Duluth, MN
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
A Single-Dose, PK/PD, & Safety Study of BIIB017 in Subjects With Renal Impairment & Healthy Volunteers
An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Clinical Research Facility
mi
from
Miami Gardens, FL
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami Gardens, FL
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Clinical Research Facility
mi
from
Orlando, FL
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Orlando, FL
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Clinical Research Facility
mi
from
St. Paul, MN
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
St. Paul, MN
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Clinical Research Facility
mi
from
Knoxville, TN
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Knoxville, TN
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
Status: Archived
Abington Memorial Hospital
mi
from
Abington, PA
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
Status: Archived
Updated: 1/1/1970
Abington Memorial Hospital
mi
from
Abington, PA
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
Neurocare Center for Research
mi
from
Newton, MA
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
Updated: 1/1/1970
Neurocare Center for Research
mi
from
Newton, MA
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
Updated: 1/1/1970
New York Presbyterian Hospital-Weill Cornell Medical Center
mi
from
New York, NY
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
LMI-Ablavar-401 - Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Kidney Disease Undergoing Ablavar (MRI) in Routine Clinical Practice
A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Intensive Insulin Therapy in Deceased Donors
Intensive Insulin Therapy in Deceased Donors - to Improve Renal Allograft Function and Transplanted Allograft Outcomes
Status: Archived
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Intensive Insulin Therapy in Deceased Donors
Intensive Insulin Therapy in Deceased Donors - to Improve Renal Allograft Function and Transplanted Allograft Outcomes
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
The Care Group LLC
mi
from
Indianapolis, IN
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
The Care Group LLC
mi
from
Indianapolis, IN
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
St. John Macomb
mi
from
Warren, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
St. John Macomb
mi
from
Warren, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Cardiac and Vascular Research Center of Northern Michigan
mi
from
Petoskey, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
Cardiac and Vascular Research Center of Northern Michigan
mi
from
Petoskey, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Providence Hospital
mi
from
Southfield, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
Providence Hospital
mi
from
Southfield, MI
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Ohio Health Research Institute / Riverside Methodist Hospital
mi
from
Columbus, OH
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
Ohio Health Research Institute / Riverside Methodist Hospital
mi
from
Columbus, OH
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Cardiovascular Catheterization Labs at Fairfield
mi
from
Fairfield, OH
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
Cardiovascular Catheterization Labs at Fairfield
mi
from
Fairfield, OH
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
St. Vincent Mercy Children's Hospital
mi
from
Toledo, OH
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury
Status: Archived
Updated: 1/1/1970
St. Vincent Mercy Children's Hospital
mi
from
Toledo, OH